GHRP-2: A Growth Hormone–Releasing Peptide in Research

For laboratory research use only.

GHRP-2—also published under names such as pralmorelin and KP-102—is a synthetic hexapeptide growth hormone–releasing peptide developed from the GHRP series. It remains one of the stronger GHS-R1a agonists used as a reference tool in secretagogue research.

Identity under several names

Secondary pharmacology summaries describe pralmorelin/GHRP-2 as a potent GH-releasing peptide with a substantial experimental record across administration routes studied in animals and humans in older literature (pralmorelin/GHRP-2 profile; KP-102 characteristics). Synonyms help literature search; the lot label and sequence still control what was used in an experiment.

Potency and selectivity themes

In comparative swine data presented with ipamorelin, GHRP-2 showed higher GH-release potency than GHRP-6 or ipamorelin, with lower maximal GH efficacy than those comparators in the same report, and with ACTH/cortisol increases that ipamorelin lacked (Raun et al., 1998). Those differences are why selectivity is treated as a design variable when assembling a GHS-R1a panel rather than as a marketing slogan.

Place in the wider GH–IGF toolkit

Recent overviews of peptides that modulate the GH–IGF axis keep GHRPs in a lane separate from GHRH analogs and from IGF receptor ligands (GH–IGF peptide landscape review). GHRP-2 belongs with ghrelin-receptor tools. Pairing it experimentally with a GHRH analog is a two-pathway question, not proof that the molecules are similar.

Limits

Human and animal secretagogue papers are model- and chemotype-specific. They should be cited for the endpoints they measured, not generalized into recovery or performance claims for laboratory listings.

Sources

Shopping Cart
Scroll to Top